These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
186 related articles for article (PubMed ID: 8823240)
1. Relationship between pharmacodynamic activity and cognitive effects of eptastigmine in patients with Alzheimer's disease. Eptastigmine Study Group. Canal N; Imbimbo BP Clin Pharmacol Ther; 1996 Aug; 60(2):218-28. PubMed ID: 8823240 [TBL] [Abstract][Full Text] [Related]
2. Efficacy and safety of eptastigmine for the treatment of patients with Alzheimer's disease. Imbimbo BP; Martelli P; Troetel WM; Lucchelli F; Lucca U; Thal LJ Neurology; 1999 Mar; 52(4):700-8. PubMed ID: 10078713 [TBL] [Abstract][Full Text] [Related]
3. Effectiveness and safety of velnacrine for the treatment of Alzheimer's disease. A double-blind, placebo-controlled study. Mentane Study Group. Antuono PG Arch Intern Med; 1995 Sep; 155(16):1766-72. PubMed ID: 7654110 [TBL] [Abstract][Full Text] [Related]
4. A multicentre, randomized, double-blind, placebo-controlled study to evaluate the efficacy, tolerability and safety of two doses of metrifonate in patients with mild-to-moderate Alzheimer's disease: the MALT study. Dubois B; McKeith I; Orgogozo JM; Collins O; Meulien D Int J Geriatr Psychiatry; 1999 Nov; 14(11):973-82. PubMed ID: 10556869 [TBL] [Abstract][Full Text] [Related]
5. A 6-month, double-blind, placebo-controlled trial of eptastigmine in Alzheimer's disease. Imbimbo BP; Troetel WM; Martelli P; Lucchelli F Dement Geriatr Cogn Disord; 2000; 11(1):17-24. PubMed ID: 10629357 [TBL] [Abstract][Full Text] [Related]
8. Eptastigmine: ten years of pharmacology, toxicology, pharmacokinetic, and clinical studies. Braida D; Sala M CNS Drug Rev; 2001; 7(4):369-86. PubMed ID: 11830755 [TBL] [Abstract][Full Text] [Related]
9. Two-year treatment of Alzheimer's disease with eptastigmine. The Eptastigmine Study Group. Imbimbo BP; Verdelli G; Martelli P; Marchesini D Dement Geriatr Cogn Disord; 1999; 10(2):139-47. PubMed ID: 10026388 [TBL] [Abstract][Full Text] [Related]
10. Efficacy and safety of mixed amphetamine salts extended release (Adderall XR) in the management of attention-deficit/hyperactivity disorder in adolescent patients: a 4-week, randomized, double-blind, placebo-controlled, parallel-group study. Spencer TJ; Wilens TE; Biederman J; Weisler RH; Read SC; Pratt R Clin Ther; 2006 Feb; 28(2):266-79. PubMed ID: 16678648 [TBL] [Abstract][Full Text] [Related]
11. A randomized, double-blind, placebo-controlled study of the efficacy and safety of donepezil in patients with Alzheimer's disease in the nursing home setting. Tariot PN; Cummings JL; Katz IR; Mintzer J; Perdomo CA; Schwam EM; Whalen E J Am Geriatr Soc; 2001 Dec; 49(12):1590-9. PubMed ID: 11843990 [TBL] [Abstract][Full Text] [Related]
12. Donepezil preserves cognition and global function in patients with severe Alzheimer disease. Black SE; Doody R; Li H; McRae T; Jambor KM; Xu Y; Sun Y; Perdomo CA; Richardson S Neurology; 2007 Jul; 69(5):459-69. PubMed ID: 17664405 [TBL] [Abstract][Full Text] [Related]
13. A multiple-dose safety trial of eptastigmine in Alzheimer's disease, with pharmacodynamic observations of red blood cell cholinesterase. Sramek JJ; Block GA; Reines SA; Sawin SF; Barchowsky A; Cutler NR Life Sci; 1995; 56(5):319-26. PubMed ID: 7837931 [TBL] [Abstract][Full Text] [Related]
14. Maximum tolerated dose and pharmacodynamics of eptastigmine in elderly healthy volunteers. Mant T; Troetel WM; Imbimbo BP J Clin Pharmacol; 1998 Jul; 38(7):610-7. PubMed ID: 9702845 [TBL] [Abstract][Full Text] [Related]
15. A 25-week placebo-controlled study of eptastigmine in patients with Alzheimer disease. Imbimbo BP; Lucca U; Lucchelli F; Alberoni M; Thal LJ Alzheimer Dis Assoc Disord; 1998 Dec; 12(4):313-22. PubMed ID: 9876959 [TBL] [Abstract][Full Text] [Related]
16. A double-blind, placebo-controlled multicenter study of tacrine for Alzheimer's disease. The Tacrine Collaborative Study Group. Davis KL; Thal LJ; Gamzu ER; Davis CS; Woolson RF; Gracon SI; Drachman DA; Schneider LS; Whitehouse PJ; Hoover TM N Engl J Med; 1992 Oct; 327(18):1253-9. PubMed ID: 1406817 [TBL] [Abstract][Full Text] [Related]
17. Double-blind placebo-controlled study with citicoline in APOE genotyped Alzheimer's disease patients. Effects on cognitive performance, brain bioelectrical activity and cerebral perfusion. Alvarez XA; Mouzo R; Pichel V; Pérez P; Laredo M; Fernández-Novoa L; Corzo L; Zas R; Alcaraz M; Secades JJ; Lozano R; Cacabelos R Methods Find Exp Clin Pharmacol; 1999 Nov; 21(9):633-44. PubMed ID: 10669911 [TBL] [Abstract][Full Text] [Related]
18. A six-month double-blind, randomized, placebo-controlled study of a transdermal patch in Alzheimer's disease--rivastigmine patch versus capsule. Winblad B; Cummings J; Andreasen N; Grossberg G; Onofrj M; Sadowsky C; Zechner S; Nagel J; Lane R Int J Geriatr Psychiatry; 2007 May; 22(5):456-67. PubMed ID: 17380489 [TBL] [Abstract][Full Text] [Related]
19. Post hoc comparison of daily rates of nausea and vomiting with once- and twice-daily galantamine from a double-blind, placebo-controlled, parallel-group, 6-month study. Dunbar F; Zhu Y; Brashear HR Clin Ther; 2006 Mar; 28(3):365-72. PubMed ID: 16750451 [TBL] [Abstract][Full Text] [Related]
20. Rivastigmine and donepezil treatment in moderate to moderately-severe Alzheimer's disease over a 2-year period. Bullock R; Touchon J; Bergman H; Gambina G; He Y; Rapatz G; Nagel J; Lane R Curr Med Res Opin; 2005 Aug; 21(8):1317-27. PubMed ID: 16083542 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]